Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter, First-in-human Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SIM0532 in Adult Participants With Advanced Solid Tumors

NCT07749703 is registered in ClinicalTrials.gov with Jiangsu Simcere Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07749703
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07749703 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter, First-in-human Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SIM0532 in Adult Participants With Advanced Solid Tumors
Lead sponsor
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 31, 2026
Completion date
June 30, 2030
Enrollment
346 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

histologically or cytologically confirmed advanced solid tumors